Sophie J. Clarke
Papworth Road, Cambridge Biomedical Campus
Cambridge, ENG CB20AY, United Kingdom
Cambridge, ENG CB20AY, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
GLP-1 vasodilatation in humans with coronary artery disease is not adenosine mediated.
Journal: BMC cardiovascular disorders
Published: August 12, 2020
GLP-1 Is a Coronary Artery Vasodilator in Humans.
Journal: Journal of the American Heart Association
Published: December 21, 2018
Glucagon-Like Peptide-1-Mediated Cardioprotection Does Not Reduce Right Ventricular Stunning and Cumulative Ischemic Dysfunction After Coronary Balloon Occlusion.
Journal: JACC. Basic to translational science
Published: September 10, 2018
Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies.
Journal: Cardiovascular diabetology
Published: May 28, 2016
Glucagon-Like Peptide-1: A Promising Agent for Cardioprotection During Myocardial Ischemia.
Journal: JACC. Basic to translational science
Published: January 15, 2016
Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus.
Journal: Cardiovascular diabetology
Published: May 16, 2015
Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization.
Journal: JACC. Cardiovascular interventions
Published: June 23, 2014
Relationship between urinary sodium excretion over time and mortality in type 2 diabetes.
Journal: Diabetes care
Published: March 22, 2014
Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1.
Journal: Cardiovascular diabetology
Published: November 04, 2013
Showing 1-10 of 10
Last Updated: 09/26/2026